# Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

> **NCT00532246** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 147 (actual)

## Conditions studied

- Osteoporosis, Post-Menopausal

## Interventions

- **DRUG:** raloxifene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00532246
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2007-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532246, "Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00532246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*